Astellas Pharma | 4503

Stock Price
1,505.00
Daily Change
52.00 3.58%
Monthly
-11.08%
Yearly
-24.03%
Q2 Forecast
1,595.87
Peers Price Chg Day Year Date
2413 M3 1,877.00 -7.50 -0.40% -42.26% Apr/26
4151 Kyowa Hakko Kirin 2,631.50 5.50 0.21% -12.28% Apr/26
4502 Takeda 4,087.00 -6.00 -0.15% -9.30% Apr/26
4503 Astellas Pharma 1,505.00 52.00 3.58% -24.03% Apr/26
4506 Sumitomo Dainippon 409.00 9.00 2.25% -51.65% Apr/26
4507 Shionogi 7,321.00 188.00 2.64% 20.85% Apr/26
4519 Chugai Pharma 4,856.00 -24.00 -0.49% 41.62% Apr/26
4523 Eisai 6,240.00 -19.00 -0.30% -19.52% Apr/26
4543 Terumo 2,608.50 15.50 0.60% -34.71% Apr/26
4568 Daiichi Sankyo 5,003.00 239.00 5.02% 6.22% Apr/26
4578 Otsuka Holdings 6,383.00 123.00 1.96% 40.59% Apr/26

Indexes Price Day Year Date
NKY JP225 37868 306.28 0.81% 33.07% Apr/26

Astellas Pharma traded at 1,505.00 this Friday April 26th, increasing 52.00 or 3.58 percent since the previous trading session. Looking back, over the last four weeks, Astellas Pharma gained 11.08 percent. Over the last 12 months, its price fell by 24.03 percent. Looking ahead, we forecast Astellas Pharma to be priced at 1,595.87 by the end of this quarter and at 1,467.80 in one year, according to Trading Economics global macro models projections and analysts expectations.

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.